Trent:₹3,256.10+30.96 (+0.96%)
Reliance Industries:₹1,377.50+1.93 (+0.14%)
Adani Ports:₹1,917.00-0.19 (-0.01%)
Tata Consumer:₹1,155.90+11.90 (+1.04%)
Titan Company:₹4,620.00-79.90 (-1.70%)
TCS:₹2,376.20+33.50 (+1.43%)
Trent:₹3,256.10+30.96 (+0.96%)
Reliance Industries:₹1,377.50+1.93 (+0.14%)
Adani Ports:₹1,917.00-0.19 (-0.01%)
Tata Consumer:₹1,155.90+11.90 (+1.04%)
Titan Company:₹4,620.00-79.90 (-1.70%)
TCS:₹2,376.20+33.50 (+1.43%)
Refer & Earn
Arihant Plus App

Arihant Plus App

Parmax Pharma Ltd

Parmax Pharma | 540359

Market Closed
₹135.10
+₹0.09 (+0.07%)
As on 22/11/26, 9:29 PM
Market Cap--- CR
Current Price₹---
High / Low₹--- / ---
PE Ratio---
Book Value₹---
Dividend Yield---
ROCE---
ROE0.00%
Face Value₹2.00
Current Vol.---
Average Vol.---
ISININE240T01014
PB Ratio---
Debt to Equity---
Net Profit Margin---
Operating Margin---

- Share Price Chart

+₹0.00 (+0.00%)6M

Stock Performance

₹135₹135
₹135.1
Previous CloseToday's Open
₹22.6₹139.1
₹135.1
52W Low52W High
₹135Today's Open
₹135Previous Close
5,334Volume
₹22.652W Low
₹139.152W High

Ratios

📊

Consolidated data not available

Please try selecting a different data type

About Company

  • Incorporated in November, 1994, Parmax Pharma Limited (PPL) was promoted by Jayantilal S Dhol, Purushottam J Bhalodi and Prabhudas D Hansalpara
  • The Active Pharmaceutical Ingredients (API) and Contract Manufacturing Operations ( CMO) business are the key pillar of Parmax's pharmaceutical operations
  • The Company has manufacturing facilities approved by Indian regulatory bodies such as CDSCO, State FDA, and operates under GMP-compliant systems
  • The Promoters were earlier into manufacturing of bulk drugs like Ampicilin, Amoxycillin, Cephalexin, Nalidixic Acid etc
  • The Company then discontinued their business activities for few years due to various reasons
  • Starting from their journey as a bulk drug manufacturer and speciality chemicals in 1994; the Company had set up a plant to manufacture and market bulk drugs like amoxycillin tri-hydrate, ampicillin tri-hydrate, cephalexin mono hydrate and nalidixic acid, at Hadamtala, Gujarat, with an installed capacity of 96 TPA
  • Antibiotic project was fully implemented from 31st May'97
  • The core segments of the Company comprise of Anti-Infectives, Analgesics & anti-inflammatory; Cardiovascular APIs and General oral formulations (tablets, capsules)
  • Apart from this, the Company works a stable growth in API volumes due to consistent domestic demand
  • It has marginal increase in pricing due to higher input costs passed on

Research Calls

Research Calls
Locked Access

Explore all active research calls & maximize your profits

To access, login or signup with ArihantPlus

Technical Indicators

RSIN/A
SMA 20N/A
SMA 50N/A
SMA 100N/A
SMA 200N/A
SMA 10N/A
MACD_12_26_DaysN/A
EMA10DayN/A
EMA20DayN/A
EMA50DayN/A
MACD_12_26_9_DaysN/A
EMA100DayN/A
EMA200DayN/A

Pivot Points

Volume Analysis
📊

No Information Available

Volume Analysis data is not available at this time.

Growth Rate
📊

No Information Available

Growth Rate information is not available at this time.

All figures in ₹ Crores

📊

No Information Available

No profit & lossdata available

Show % Change
ShareHolding
📊

No Information Available

No shareholding data available at this time.

📊

No Data Available

No Block Deals data available for this company.

News

17 Nov 2026 12:00 am

Parmax Pharma reports standalone net profit of Rs 0.17 crore in the September 2026 quarter

Parmax Pharma reports standalone net profit of Rs 0.17 crore in the September 2026 quarter

Record Date
Corporate Action
Information
Announcement Day
29 Sept 2026
AGM
AGM
07 Sept 2026
02 Jul 2026
EGM
EGM
08 Jun 2026
27 May 2026
EGM
EGM
04 May 2026
30 Sept 2025
AGM
AGM
16 Sept 2025
30 Sept 2024
AGM
AGM
17 Sept 2024
29 Sept 2023
AGM
AGM
16 Aug 2023
30 Sept 2022
AGM
AGM
08 Sept 2022

Peers

LTP(₹)
Market Cap(₹ Cr.)
P/E Ratio(Ratio)
P/B Ratio(Ratio)
Cash Earnings(Ratio)
Debt to Equity(Ratio)
Net Profit Ratio(%)
135
0
1,885
4,52,299
37
5
30
0
19.78%
11,200
2,97,325
87
17
76
0
24.32%
4,699
1,78,727
82
10
44
1
11.09%
2,295
1,24,002
93
20
68
1
13.06%
1,195
1,19,207
26
4
18
0
9.82%
1,391
1,16,145
41
3
24
0
12.34%
1,415
1,14,312
37
3
26
0
9.92%
2,660
1,09,870
47
6
34
0
13.57%
1,795
1,03,298
25
3
17
0
10.41%
Showing 10 of 141 Results

Frequently Asked Questions

What is Share Price of Parmax Pharma Ltd?

The current share price of Parmax Pharma Ltd (Parmax Pharma) is ₹135.10. This price reflects the latest market valuation and is updated in real-time during trading hours.

What is the 52-week high and low of Parmax Pharma Ltd?

Parmax Pharma Ltd has a 52-week high of ₹139.10 and a 52-week low of ₹22.60. This range shows the stock's price volatility over the past year.

What is the ROE of Parmax Pharma Ltd?

Parmax Pharma Ltd has a Return on Equity (ROE) of 0.00%. ROE measures how effectively the company uses shareholders' equity to generate profits, with higher values generally indicating better performance.

Disclaimer:

Please note that the above list and information is for research purposes only and are not recommendations. Do your own due diligence or consult an investment advisor before investing. The above data is dynamic in nature and subject to real-time changes and is derived from CMOTS.

mobile

Ready to invest smarter?
Download the app today.

GET IT ON

GET IT ON

Google Play

4.5

DOWNLOAD ON THE

DOWNLOAD ON THE

App Store

4.2